What if established cancer therapies could work more effectively?

Each year, approximately 4.8 million newly diagnosed cancer patients receive a thymidylate synthase, TS, directed therapy at some point during their treatment.

These therapies, including 5-fluorouracil, capecitabine, and pemetrexed, form a cornerstone of care across major cancers, including colorectal, breast, gastric, pancreatic, lung, and head and neck.

TS-directed therapies are used across multiple lines of treatment, including first-line, second-line, and maintenance therapy.

When both newly treated patients and those continuing therapy are considered, approximately 10 million patients receive a TS-directed therapy each year globally.

Global cancer incidence is projected to approach 30 million cases annually by 2040, representing an increase of approximately 47 percent from 2020 levels, based on GLOBOCAN estimates.